These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 34681910)
1. Myelodysplastic Syndromes and Metabolism. Balaian E; Wobus M; Bornhäuser M; Chavakis T; Sockel K Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681910 [TBL] [Abstract][Full Text] [Related]
2. Bone marrow niche in the myelodysplastic syndromes. Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090 [TBL] [Abstract][Full Text] [Related]
3. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? Pleyer L; Valent P; Greil R Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944 [TBL] [Abstract][Full Text] [Related]
4. The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression. Li AJ; Calvi LM Exp Hematol; 2017 Nov; 55():3-18. PubMed ID: 28826860 [TBL] [Abstract][Full Text] [Related]
5. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes. Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917 [TBL] [Abstract][Full Text] [Related]
6. Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis. Wenk C; Garz AK; Grath S; Huberle C; Witham D; Weickert M; Malinverni R; Niggemeyer J; Kyncl M; Hecker J; Pagel C; Mulholland CB; Müller-Thomas C; Leonhardt H; Bassermann F; Oostendorp RAJ; Metzeler KH; Buschbeck M; Götze KS Blood Adv; 2018 Dec; 2(23):3447-3461. PubMed ID: 30518537 [TBL] [Abstract][Full Text] [Related]
8. Biology of the bone marrow microenvironment and myelodysplastic syndromes. Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353 [TBL] [Abstract][Full Text] [Related]
9. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression. Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276 [TBL] [Abstract][Full Text] [Related]
10. What is the role of the microenvironment in MDS? Calvi LM; Li AJ; Becker MW Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976 [TBL] [Abstract][Full Text] [Related]
11. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution. Ainciburu M; Ezponda T; Berastegui N; Alfonso-Pierola A; Vilas-Zornoza A; San Martin-Uriz P; Alignani D; Lamo-Espinosa J; San-Julian M; Jiménez-Solas T; Lopez F; Muntion S; Sanchez-Guijo F; Molero A; Montoro J; Serrano G; Diaz-Mazkiaran A; Lasaga M; Gomez-Cabrero D; Diez-Campelo M; Valcarcel D; Hernaez M; Romero JP; Prosper F Elife; 2023 Jan; 12():. PubMed ID: 36629404 [TBL] [Abstract][Full Text] [Related]
12. Physician Education: Myelodysplastic Syndrome. Yoshida Y Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004 [TBL] [Abstract][Full Text] [Related]
13. Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications. Mies A; Bulycheva E; Rogulj IM; Hofbauer LC; Platzbecker U Curr Pharm Des; 2016; 22(16):2323-32. PubMed ID: 26916019 [TBL] [Abstract][Full Text] [Related]
14. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes. Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928 [TBL] [Abstract][Full Text] [Related]
15. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566 [TBL] [Abstract][Full Text] [Related]
16. [Senescent Mesenchymal Stem Cells Contribute to Progression of Myelodysplastic Syndromes-Review]. Pang YB; Li WW; Luo JM; Ji J; DU X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):942-946. PubMed ID: 29950248 [TBL] [Abstract][Full Text] [Related]
17. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes. Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751 [TBL] [Abstract][Full Text] [Related]
18. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy. Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819 [TBL] [Abstract][Full Text] [Related]
19. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. Oliveira FM; Lucena-Araujo AR; Favarin Mdo C; Palma PV; Rego EM; Falcão RP; Covas DT; Fontes AM Exp Hematol; 2013 Feb; 41(2):198-208. PubMed ID: 23092930 [TBL] [Abstract][Full Text] [Related]
20. In Vitro Insights Into the Influence of Marrow Mesodermal/Mesenchymal Progenitor Cells on Acute Myelogenous Leukemia and Myelodysplastic Syndromes. Liesveld J; Galipeau J Stem Cells; 2023 Sep; 41(9):823-836. PubMed ID: 37348128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]